The Phase II study of crizotinib in advanced NSCLC harboring MET amplification reported RR in low (>1.8–<2.2), intermediate (>2.2–<5) and high (>5) MET/CEP7 ratios of 0, 20, and 50%, respectively (42). The gene discussed is MET; the disease is non-small cell lung carcinoma.